Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCB001158 + oxaliplatin + leucovorin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral (INCB001158), Intravenous (oxaliplatin), Intravenous (leucovorin), Intravenous (5-fluorouracil)
01
Overview
INCB001158 + oxaliplatin + leucovorin + 5-fluorouracil is a combination therapy composed of the experimental small molecule arginase inhibitor INCB001158 with standard anticancer cytotoxic agents oxaliplatin, leucovorin, and 5-fluorouracil. INCB001158 inhibits arginase-1, an immunosuppressive enzyme produced by myeloid-derived suppressor cells in the tumor microenvironment, leading to increased arginine levels, reversal of local T cell suppression, and enhanced anti-tumor immune response. Oxaliplatin is a platinum-based DNA crosslinking agent, 5-fluorouracil is a pyrimidine antagonist that inhibits thymidylate synthase disrupting DNA replication, and leucovorin enhances the effect of 5-fluorouracil. The combination is under clinical investigation in advanced/metastatic solid tumors, particularly gastrointestinal/colorectal malignancies, aiming to improve anti-tumor immune activity and cytotoxicity[1][5][6][8].
- Brand names
- None known for the combination
- Other names
- None known for the combination
02
Targets
DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)DNAARG1 (Arginase 1)
Beyond the preview
Go deeper on INCB001158 + oxaliplatin + leucovorin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCB001158 + oxaliplatin + leucovorin + 5-fluorouracil.